Zosano Pharma (ZSAN) Financials

$0.30

$-0.03 (-9.23%)

As on 08-Jul-2022 09:30EDT

Market cap

$3 Mln

Revenue (TTM)

$1 Mln

P/E Ratio

--

P/B Ratio

0.2

Div. Yield

0 %

Annual
Quarterly

Income Statement ($ Mln)	TTM	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16	Dec-15	Dec-14	Dec-13	Dec-12
Operating Revenue	0.66	0.79	0.22	--	--	--
Cost of Revenue	0.72	0.80	0.17	25.39	25.51	20.12
Gross Profit	-0.06	-0.01	0.05	-25.39	-25.51	-20.12
Operating Expenses	30.80	31.52	32.81	37.20	34.87	28.37
Operating Profit (EBIT)	-56.80	-31.53	-32.76	-37.20	-35.38	-28.37
Other Income	1.85	--	0.11	0.13	0.40	0.01
Profit before Tax	-55.19	-29.93	-33.37	-37.59	-35.36	-29.11
Provision for Tax	--	--	--	--	--	--
Profit after Tax (Net Income)	-55.19	-29.93	-33.37	-37.59	-35.36	-29.11
Minority Interest	--	--	--	--	--	--
Consolidated Profit	-55.19	-29.93	-33.37	-37.59	-35.36	-29.11

Liabilities ($ Mln)	TTM	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16	Dec-15	Dec-14	Dec-13	Dec-12
Shareholder's Funds	14.05	32.98	47.52	9.39	18.71	7.05
Minority Interest	--	--	--	--	--	--
Non-Current Liabilities	2.66	4.28	9.99	12.04	5.78	0.50
Current Liabilities	9.73	11.13	14.51	16.24	11.29	10.46
Total Liabilities	36.18	48.39	72.01	37.67	35.78	18.00

Assets ($ Mln)	TTM	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16	Dec-15	Dec-14	Dec-13	Dec-12
Non-Current Assets	10.81	36.78	36.30	30.86	12.42	4.61
Current Assets	15.63	11.61	35.72	6.81	23.36	13.39
Total Assets	36.18	48.39	72.01	37.67	35.78	18.00
Total Debt*	6.04	9.48	16.82	17.75	6.83	6.69
Net Current Assets	5.90	0.48	21.21	-9.42	12.07	2.94

Cashflow ($ Mln)	TTM	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16	Dec-15	Dec-14	Dec-13	Dec-12
Cash From Operating Activities	--	-27.59	-31.72	-34.82	-29.12	-27.12
Cash Flow from Investing Activities	--	-5.42	-8.49	2.16	-19.21	-1.23
Cash from Financing Activities	--	8.79	69.15	29.83	45.82	25.00
Net Cash Inflow / Outflow	--	--	28.95	-2.82	-2.51	-3.35

Financials Ratios	TTM	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16	Dec-15	Dec-14	Dec-13	Dec-12
Adjusted EPS ($)	--	--	--	--	--	--
Cash EPS ($)	--	--	--	--	--	--
Adjusted Book Value ($)	--	--	--	--	--	--
Dividend per Share ($)	--	--	--	--	--	--
Cash Flow per Share ($)	--	--	--	--	--	--
Free Cash Flow per Share ($)	--	--	--	--	--	--

Profitability Ratios	TTM	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16	Dec-15	Dec-14	Dec-13	Dec-12
ROCE (%)	--	-56.04	-72.95	-142.70	-180.07	-189.23
ROE (%)	-211.23	-74.36	-117.28	-267.52	-274.54	-504.73
ROA (%)	-94.92	-49.71	-60.85	-102.35	-131.49	-149.62
EBIT Margin (%)	-8,350.08	-3,788.03	-14,575.89	--	--	--
Net Margin (%)	-2,199.76	-3,812.10	-10,050.90	-28,693.89	-8,906.30	-415,785.71
Cash Profit Margin (%)	-0.01	--	--	--	--	--

Growth Ratios	TTM	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16	Dec-15	Dec-14	Dec-13	Dec-12
Revenue Growth (%)	36.72	2.50	--	--	--	--
EBIT Growth (%)	-128.26	8.92	11.91	-6.31	-22.89	0.92
Net Profit Growth (%)	-123.23	10.32	11.23	-6.31	-21.48	2.44
EPS Growth (%)	--	--	--	--	--	--
Book Value Growth (%)	--	--	--	--	--	--

Valuation Ratios	TTM	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16	Dec-15	Dec-14	Dec-13	Dec-12
Price / Earnings	--	--	--	--	--	--
Price / Book Value	0.16	--	--	--	--	--
Dividend Yield (%)	--	--	--	--	--	--
EV/EBITDA	0.10	0.06	0.59	-0.31	0.47	0.19
Close Price ($)	7.88	16.45	18.45	53.20	74.20	364.00
High Price ($)	45.50	107.10	68.60	232.75	899.50	2,477.30
Low Price ($)	3.95	16.12	11.46	44.45	64.75	350.00
Market Cap ($ Cr)	2.73	--	--	--	--	--

Solvency Ratios	TTM	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16	Dec-15	Dec-14	Dec-13	Dec-12
Debt to Equity	--	0.29	0.35	1.89	0.36	0.95
Short term debt to equity ratio	0.24	0.16	0.15	0.61	0.12	0.95
Current Ratio	1.61	1.04	2.46	0.42	2.07	1.28
Quick Ratio	1.61	--	--	--	--	1.28
Interest Coverage	-333.50	--	--	--	--	--

Operating Efficiency Ratios	TTM	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16	Dec-15	Dec-14	Dec-13	Dec-12
Debtors to sales (%)	16.24	18.60	55.36	--	--	--
Asset Turnover	0.01	0.01	0.00	--	--	--
Receivable days	--	62.81	202.19	--	--	--
Inventory Days	--	--	--	--	--	--
Payable days	--	918.63	6,664.21	63.35	42.68	48.46
Cash Conversion Cycle	--	--	--	--	--	--

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.